Zobrazeno 1 - 10
of 11
pro vyhledávání: '"BlakeKathryn"'
Publikováno v:
Pediatric allergy, immunology, and pulmonology. 27(2)
Cystic fibrosis (CF) is a common autosomal recessive inherited disorder affecting 1 in 2,500 births and ∼75,000 people in North America, Europe, and Australia. The purpose of this review is to discuss the most recent advances in therapies for CF pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e479d1012d34c7b8218cc9d592e54ab1
https://pubmed.ncbi.nlm.nih.gov/35923012
https://pubmed.ncbi.nlm.nih.gov/35923012
Autor:
RaissyHengameh, BlakeKathryn
Publikováno v:
Pediatric allergy, immunology, and pulmonology. 29(3)
The safety of cough and cold products for pediatric use has been a concern of regulatory agencies and advocacy groups for decades. Most recently, the Food and Drug Administration requested input from Pulmonary-Allergy Drugs and Drug Safety and Risk M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd8616700e9d016b8518468f128cab9b
https://pubmed.ncbi.nlm.nih.gov/35923051
https://pubmed.ncbi.nlm.nih.gov/35923051
Autor:
BlakeKathryn, RaissyHengameh
Publikováno v:
Pediatric allergy, immunology, and pulmonology. 30(3)
Patients with cystic fibrosis are experimenting with inhaling essential oils (scientifically described as random plant-derived secondary metabolites) through diffusers or nebulizers as a form of natural therapy to treat chronic lung infections.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e71a988430e0f119d5f40f47f658ae6
https://pubmed.ncbi.nlm.nih.gov/35923005
https://pubmed.ncbi.nlm.nih.gov/35923005
Autor:
H RaissyHengameh, V BlakeKathryn
Publikováno v:
Pediatric Allergy, Immunology, and Pulmonology. 31:199-203
The National Asthma Education and Prevention Program Guidelines for the Diagnosis and Management of Asthma are slated to be updated on 6 topic areas. This review summarizes the findings for the cha...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddc054dc909ec0f2e755de495b0b8dbf
https://doi.org/10.1089/ped.2018.0942
https://doi.org/10.1089/ped.2018.0942
Autor:
RaissyHengameh, BlakeKathryn
Publikováno v:
Pediatric Allergy, Immunology, and Pulmonology. 31:107-109
There are limited data as how to manage the “yellow zone” in children with asthma. Although increasing the dose of inhaled corticosteroids (ICSs) has been practiced by some providers, the efficacy ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::556b7394044759de49f1ef57d9ddd3bf
https://doi.org/10.1089/ped.2018.0902
https://doi.org/10.1089/ped.2018.0902
Autor:
RaissyHengameh, BlakeKathryn
Publikováno v:
Pediatric Allergy, Immunology, and Pulmonology. 31:37-39
The National Asthma Education and Prevention Program Guidelines for the Diagnosis and Management of Asthma were last published in 2007. New therapies and strategies for asthma management have been ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbc4b32c3672e96dcd991cbccd264d4e
https://doi.org/10.1089/ped.2018.0878
https://doi.org/10.1089/ped.2018.0878
Autor:
RaissyHengameh, BlakeKathryn
Publikováno v:
Pediatric Allergy, Immunology, and Pulmonology. 29:49-52
Mepolizumab and reslizumab are anti-interleukin-5 monoclonal antibodies. Mepolizumab has been approved by the Food and Drug Administration (FDA) as add-on therapy for patients 12 years and older with severe asthma with an eosinophil phenotype. Resliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb93b63524e943d2f085ec114a571131
https://doi.org/10.1089/ped.2016.0631
https://doi.org/10.1089/ped.2016.0631
Autor:
BlakeKathryn, RaissyHengameh
Publikováno v:
Pediatric Allergy, Immunology, and Pulmonology. 30:129-131
Use of acetaminophen and increasing risk of asthma have been reported in the epidemiological studies. Despite lack of controlled prospective clinical trials evaluating these associations in children, avoidance of acetaminophen in children with asthma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c75e4d4f152223c2995bc9665681740
https://doi.org/10.1089/ped.2017.0767
https://doi.org/10.1089/ped.2017.0767
Autor:
RaissyHengameh, BlakeKathryn
Publikováno v:
Pediatric Allergy, Immunology, and Pulmonology. 27:143-146
A new product, Epinephrine HFA, is being considered by the Food and Drug Administration (FDA) for marketing approval as a nonprescription bronchodilator inhaler for the treatment of the “temporary relief of mild symptoms of intermittent asthma in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17300eba45a72c823d0015acfd317e3a
https://doi.org/10.1089/ped.2014.0399
https://doi.org/10.1089/ped.2014.0399
Autor:
BlakeKathryn, RaissyHengameh
Publikováno v:
Pediatric Allergy, Immunology, and Pulmonology. 28:129-131
Several international and national organizations have developed guidelines for the treatment of allergic rhinitis, or rhinitis more broadly, but most are now 5 years old or more. The American Academy of Otolaryngology—Head and Neck Surgery recently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d10429850a39d7039fec187cc0891c0b
https://doi.org/10.1089/ped.2015.0519
https://doi.org/10.1089/ped.2015.0519